Category Archives: Covering medical studies

NIH leader to headline Journalism Summit on Infectious Disease

Pia Christensen

About Pia Christensen

Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates AHCJ's social media efforts and edits and manages production of association guides, programs and newsletters.

Francis Collins

Francis Collins

Francis Collins, director of the National Institutes of Health, will be a featured speaker at the Association of Health Care Journalists’ Summit on Infectious Disease next month.

AHCJ has recruited experts and leading health care journalists to discuss data resources, treatments and vaccine development, health workers and vulnerable populations, COVID-19 and influenza sharing a season. Continue reading

Follow COVID-19 research money to find stories near you

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

scientist-with-microscopeThe timeless advice sometimes attributed to Deep Throat or Bob Woodard and Carl Bernstein to “follow the money” certainly applies to COVID-19.

For reporters looking for local stories, follow the money doled out by the National Institutes of Health for COVID-19 research. Most recently, the National Cancer Institute, which received $306 million from Congress through the Coronavirus Aid, Relief, and Economic Security Act, announced the first grants and contracts to researchers to form the Serological Sciences Network for COVID-19. Continue reading

Watch out for these red flags in COVID-19 vaccine trials

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

syringes

Photo: Jernej Furman via Flickr

In a previous blog post, I discussed what reporters look for when they dig into the data from the various COVID-19 vaccine clinical trials. That post covered the do’s, but it didn’t cover the red flags that reporters should watch for as well.

Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco, followed up his Twitter thread on what to look for with a list of common problems in vaccine clinical trials that journalists also should monitor: Continue reading

What to look for in COVID-19 vaccine trials

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Coronavirus CG Illustration

Photo: Yuri Samoilov via Flickr

As various COVID-19 vaccine candidates make their way through clinical trials — see this nice update on where things stand from Helen Branswell at STAT — journalists need to be scrutinizing the findings as closely as possible when reporting on them. But what do you look for?

The questions I include from this piece from Elemental, primarily aimed at laypersons, are a good starting point. Then, getting more detailed, look to this brief thread of tweets from Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco. Continue reading

How reporting on people’s intent to get a COVID-19 vaccine can harm public health

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

syringe

Photo: F&Prtw via Flickr

A recent Pew Research poll found that the proportion of Americans who said they would get a COVID-19 vaccine when it is released has dropped sharply since May. This isn’t necessarily very surprising, given the federal administration’s shenanigans with the CDC, documented in excellent reporting at Politico by Dan Diamond and the NYT by Apoorva Mandavilli. Then there’s the experience at the FDA, where emergency use authorizations were used for hydroxychloroquine and convalescent plasma before adequate evidence to support either one was available. Continue reading

Study says older adults vastly underrepresented in COVID-19 trials

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Elderly couple wearing masks

Photo: Babette Plana via Flickr

Approximately 80% of COVID-19 related deaths in the United States have been among people 65 or older, according to the Centers for Disease Control and Prevention. But a research letter published online in JAMA Internal Medicine on Sept. 28 reported that more than half of COVID-19 clinical trials were “at high risk for excluding older adults,” and none included seniors as part of vaccine trials early in the pandemic.

Despite a National Institute of Health policy mandating the inclusion of older adults in appropriate clinical trials, older adults were left out more often than not as scientists struggled to get a handle on the coronavirus. Researchers found that 53% of trials they reviewed did not include those older than 65 for a variety of reasons, including compliance concerns, co-morbid conditions or technology requirements. About one in four of the trials reviewed by the researchers included an age “cutoff” that would exclude adults age 65 to 80, as UPI reported. Continue reading